Armata Pharmaceuticals, Inc.
ARMP
$5.41
-$0.41-7.05%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.54M | 5.20M | 4.90M | 5.05M | 6.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.54M | 5.20M | 4.90M | 5.05M | 6.87M |
| Cost of Revenue | 17.59M | 16.40M | 15.72M | 17.70M | 21.36M |
| Gross Profit | -12.05M | -11.20M | -10.81M | -12.64M | -14.49M |
| SG&A Expenses | 23.24M | 20.62M | 20.41M | 20.71M | 20.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.83M | 37.02M | 36.13M | 38.40M | 42.20M |
| Operating Income | -35.28M | -31.82M | -31.22M | -33.35M | -35.33M |
| Income Before Tax | -192.18M | -282.61M | -173.80M | -46.90M | -25.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -192.18 | -282.61 | -173.80 | -46.90 | -25.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -192.18M | -282.61M | -173.80M | -46.90M | -25.71M |
| EBIT | -35.28M | -31.82M | -31.22M | -33.35M | -35.33M |
| EBITDA | -33.45M | -30.21M | -29.69M | -31.86M | -33.89M |
| EPS Basic | -5.30 | -7.76 | -4.79 | -1.30 | -0.71 |
| Normalized Basic EPS | -0.96 | -0.86 | -0.82 | -0.83 | -0.84 |
| EPS Diluted | -7.59 | -7.77 | -4.81 | -1.91 | -1.32 |
| Normalized Diluted EPS | -0.85 | -0.86 | -0.74 | -0.66 | -0.66 |
| Average Basic Shares Outstanding | 145.86M | 145.30M | 144.96M | 144.79M | 144.74M |
| Average Diluted Shares Outstanding | 171.15M | 145.30M | 168.25M | 190.98M | 190.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |